DCTH
Delcath Systems, Inc. NASDAQ Listed May 3, 2018$11.69
-2.01%
vs $11.93
Mkt Cap $403.6M
52w Low $8.12
56.1% of range
52w High $14.48
50d MA $11.01
200d MA $10.24
P/E (TTM)
172.9x
EV/EBITDA
97.3x
P/B
3.8x
Debt/Equity
0.0x
ROE
2.4%
P/FCF
22.3x
RSI (14)
61.00
ATR (14)
$0.58
Beta
0.43
50d MA
$11.01
200d MA
$10.24
Avg Volume
565.9K
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
1633 Broadway · New York City, NY 10019 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | BMO | — | — | — | 11.26 | +2.2% | -0.2% | +2.1% | -3.7% | +2.5% | +2.4% | — |
| Feb 26, 2026 | AMC | -0.06 | -0.05 | +20.6% | 9.00 | +0.1% | -1.1% | +0.3% | -3.7% | +7.3% | -1.6% | — |
| Nov 4, 2025 | AMC | 0.02 | 0.02 | +0.0% | 9.08 | -1.7% | -4.4% | -0.5% | +0.0% | -0.7% | +0.5% | — |
| Aug 6, 2025 | AMC | 0.03 | 0.07 | +169.2% | 10.64 | +2.3% | -4.2% | -1.8% | +5.0% | +3.5% | +2.1% | — |
| May 8, 2025 | AMC | 0.10 | 0.03 | -70.0% | 14.36 | +0.1% | +3.3% | -2.6% | +5.8% | +1.2% | +3.7% | — |
| Mar 6, 2025 | AMC | -0.10 | 0.05 | +150.0% | 13.22 | +2.1% | -1.7% | -9.2% | -0.1% | +3.5% | -1.1% | — |
| Nov 8, 2024 | AMC | -0.13 | -0.03 | +76.9% | 11.06 | +1.8% | -9.9% | -2.6% | -3.0% | -1.9% | +1.7% | — |
| Aug 5, 2024 | AMC | -0.34 | -0.48 | -41.2% | 8.32 | +1.2% | -4.9% | -1.5% | +3.3% | -3.4% | -4.0% | — |
| May 14, 2024 | AMC | -0.43 | -0.43 | +0.0% | 7.07 | +4.8% | +1.7% | -3.2% | +8.8% | +6.1% | +0.7% | — |
| Mar 26, 2024 | AMC | -0.67 | -0.48 | +28.4% | 4.61 | +2.4% | +10.4% | -6.3% | +0.4% | -1.9% | +3.6% | — |
| Nov 13, 2023 | AMC | -0.51 | -0.61 | -19.6% | 2.98 | -1.0% | -24.5% | +4.9% | +4.7% | -0.8% | +10.2% | — |
| Aug 9, 2023 | AMC | -0.67 | -0.58 | +13.4% | 3.87 | -0.3% | -16.5% | -2.2% | -1.3% | +81.7% | -4.6% | — |
| May 22, 2023 | AMC | -0.57 | -0.77 | -35.1% | 7.05 | +1.4% | +1.6% | +2.8% | +2.6% | +2.1% | +1.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 26 | BTIG | Maintains | Buy → Buy | — | $10.21 | $9.43 | -7.6% | -11.9% | -1.1% | +0.3% | -3.7% | +7.3% |
| Jan 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.21 | $10.31 | +1.0% | +1.3% | -0.5% | +1.3% | -0.4% | -1.6% |
| Nov 5 | Stephens & Co. | Maintains | Overweight → Overweight | — | $9.08 | $8.93 | -1.7% | -4.4% | -0.5% | +0.0% | -0.7% | +0.5% |
| Nov 4 | BTIG | Maintains | Buy → Buy | — | $9.52 | $9.08 | -4.6% | -4.6% | -4.4% | -0.5% | +0.0% | -0.7% |
| Oct 21 | Canaccord Genuity | Maintains | Buy → Buy | — | $11.42 | $11.40 | -0.2% | -0.3% | -9.0% | +0.2% | -1.4% | -2.3% |
| Oct 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.97 | $10.54 | -11.9% | -4.6% | -0.3% | -9.0% | +0.2% | -1.4% |
| Aug 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.64 | $10.89 | +2.3% | -4.2% | -1.8% | +5.0% | +3.5% | +2.1% |
| Jun 23 | Stephens & Co. | Maintains | Overweight → Overweight | — | $13.85 | $13.32 | -3.8% | -4.3% | +4.6% | +0.5% | +0.8% | -3.4% |
| May 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.15 | $16.21 | +0.4% | -0.2% | +1.9% | -1.3% | +5.4% | -5.0% |
| Mar 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.22 | $13.50 | +2.1% | -1.7% | -9.2% | -0.1% | +3.5% | -1.1% |
| Jan 17 | Craig-Hallum | Maintains | Buy → Buy | — | $13.67 | $14.00 | +2.4% | +4.7% | +4.7% | +1.5% | +6.0% | -0.8% |
| Jan 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.79 | $12.94 | +1.2% | -0.8% | +0.2% | +7.6% | +4.7% | +4.7% |
| Nov 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.06 | $11.26 | +1.8% | -9.9% | -2.6% | -3.0% | -1.9% | +1.7% |
| Aug 6 | Stephens & Co. | Maintains | Overweight → Overweight | — | $8.32 | $8.42 | +1.2% | -4.9% | -1.5% | +3.3% | -3.4% | -4.0% |
| Aug 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.32 | $8.42 | +1.2% | -4.9% | -1.5% | +3.3% | -3.4% | -4.0% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.07 | $7.41 | +4.8% | +1.7% | -3.2% | +8.8% | +6.1% | +0.7% |
| Mar 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.61 | $4.72 | +2.4% | +10.4% | -6.3% | +0.4% | -1.9% | +3.6% |
| Sep 7 | Canaccord Genuity | Maintains | Buy → Buy | — | $4.71 | $4.86 | +3.2% | -2.3% | +4.6% | +1.9% | -1.8% | -5.8% |
| Aug 16 | BTIG | Maintains | Buy → Buy | — | $5.67 | $5.55 | -2.1% | -4.6% | -11.3% | +4.4% | +1.4% | +8.5% |
| Aug 16 | Roth MKM | Maintains | Buy → Buy | — | $5.67 | $5.55 | -2.1% | -4.6% | -11.3% | +4.4% | +1.4% | +8.5% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.12 | $5.84 | +87.2% | +81.7% | -4.6% | -11.3% | +4.4% | +1.4% |
| Aug 15 | Canaccord Genuity | Maintains | Buy → Buy | — | $3.12 | $5.84 | +87.2% | +81.7% | -4.6% | -11.3% | +4.4% | +1.4% |
| May 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.16 | $7.15 | -0.1% | +2.8% | +2.6% | +2.1% | +1.2% | +2.1% |
| Mar 28 | Roth MKM | Maintains | Buy → Buy | — | $6.00 | $5.88 | -2.0% | -1.3% | -6.4% | +1.6% | +2.1% | +3.0% |
| Mar 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.00 | $5.88 | -2.0% | -1.3% | -6.4% | +1.6% | +2.1% | +3.0% |
| Aug 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.26 | $4.26 | +0.0% | +2.3% | +3.2% | +6.9% | -6.4% | -2.2% |
| Jun 24 | BTIG | Maintains | Buy → Buy | — | $3.88 | $3.63 | -6.4% | +1.0% | +2.3% | +2.2% | -2.7% | +0.0% |
| Dec 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.02 | $8.64 | +7.7% | +5.0% | -4.4% | -5.5% | +8.4% | -1.9% |
| Apr 6 | Roth Capital | Maintains | Buy → Buy | — | $15.10 | $15.20 | +0.7% | -7.9% | +0.7% | -3.1% | +1.6% | -6.5% |
| Mar 9 | Canaccord Genuity | Maintains | Buy → Buy | — | $17.65 | $19.28 | +9.2% | +10.4% | -3.2% | +1.2% | -1.0% | +0.3% |
| Jan 5 | BTIG | Maintains | Buy → Buy | — | $16.91 | $16.80 | -0.7% | +1.2% | +1.2% | +5.8% | -5.6% | -2.9% |
| Nov 25 | Roth Capital | Maintains | Buy → Buy | — | $17.16 | $17.95 | +4.6% | -1.7% | -0.1% | -0.6% | -5.4% | +0.9% |
| Jun 4 | Roth Capital | Maintains | Buy → Buy | — | $7.75 | $7.80 | +0.6% | +1.3% | +1.1% | +0.8% | +0.0% | +1.9% |
| Mar 4 | Wallachbeth | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| May 3 | Roth Capital | Downgrade | Buy → Sell | — | — | — | — | — | — | — | — | — |
| May 3 | JMP Securities | Downgrade | Market Outperform → Perform | — | — | — | — | — | — | — | — | — |
| May 3 | TD Cowen | Downgrade | Outperform → Underperform | — | — | — | — | — | — | — | — | — |
| May 3 | Wedbush | Downgrade | Outperform → Neutral | — | — | — | — | — | — | — | — | — |
| Mar 15 | Wedbush | Maintains | Outperform → Outperform | — | — | — | — | — | — | — | — | — |
| Jun 4 | Canaccord Genuity | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
No insider trades available.
8-K
Delcath Systems, Inc. -- 8-K Filing
May 14
8-K
Delcath Systems Inc -- 8-K Filing
Delcath Systems' percutaneous hepatic perfusion combined with ipilimumab and nivolumab showed promising results for metastatic uveal melanoma in the published CHOPIN Phase 2 trial, potentially supporting future development and commercialization efforts.
Mar 3
8-K
Delcath Systems Inc -- 8-K Filing
Delcath Systems reported its fourth quarter and full year 2025 financial results, with management hosting a conference call to discuss performance and outlook for the medical device company.
Feb 26
8-K · 5.02
!!! Very High
Nuwellis, Inc. -- 8-K 5.02: Executive Change
Nuwellis appointed Martin J. Emerson and David A. McDonald as Class I directors, potentially signaling board refreshment and strategic changes for the medical device company's governance structure.
Feb 26
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Rosalind Advisors, Inc. | 3,300,389 | $31M | — | Mar 2026 |
| 2 | Vanguard Capital Management Llc | 1,329,288 | $12M | New | Mar 2026 |
| 3 | Propel Bio Management, Llc | 979,698 | $9M | Added | Mar 2026 |
| 4 | Morgan Stanley | 617,100 | $6M | Added | Dec 2025 |
| 5 | Millennium Management | 588,055 | $5M | Added | Mar 2026 |
| 6 | Divisadero Street Capital Management, Lp | 499,796 | $5M | — | Mar 2026 |
| 7 | Northern Trust Corp | 251,863 | $2M | Added | Mar 2026 |
| 8 | Jane Street Group, Llc | 212,056 | $2M | Reduced | Dec 2025 |
| 9 | Adar1 Capital Management, Llc | 224,385 | $2M | New | Mar 2026 |
| 10 | Lane Generational Llc | 205,092 | $2M | Added | Mar 2026 |
| 11 | Marshall Wace, Llp | 191,630 | $2M | Added | Mar 2026 |
| 12 | Cibc World Market Inc. | 189,737 | $2M | Added | Mar 2026 |
| 13 | Vanguard Portfolio Management Llc | 178,036 | $2M | New | Mar 2026 |
| 14 | Renaissance Technologies Llc | 155,300 | $1M | Reduced | Mar 2026 |
| 15 | Algert Global Llc | 145,733 | $1M | Reduced | Mar 2026 |
| 16 | Nuveen, Llc | 103,774 | $963K | Added | Mar 2026 |
| 17 | Man Group Plc | 102,214 | $949K | Added | Mar 2026 |
| 18 | Bank Of New York Mellon Corp | 98,636 | $915K | Reduced | Mar 2026 |
| 19 | Capital Advisors Wealth Management, Llc | 93,000 | $863K | Added | Mar 2026 |
| 20 | Citadel Advisors Llc | 77,264 | $717K | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$403.6M
Enterprise Value
$375.6M
P/E (TTM)
172.93x
Forward P/E
—
PEG Ratio
-1.24x
P/B
3.77x
P/S
5.48x
P/FCF
22.25x
EV/EBITDA
97.34x
Shares Out
39.9M
Financials (TTM)
Revenue
$85.2M
Net Income
$2.7M
EBITDA
$3.9M
Free Cash Flow
$21.0M
Op Cash Flow
$22.5M
EPS Basic
$0.08
EPS Diluted
$0.07
EPS Forward
$-0.61
Gross Margin
86.2%
Op Margin
0.8%
Net Margin
3.2%
Balance Sheet
Total Assets
$123.6M
Total Liab.
$12.4M
Total Equity
$111.2M
Cash
$91.0M
LT Debt
$0
Book Value/Sh
$3.10
Debt/Equity
0.01x
Current Ratio
10.92
Quick Ratio
9.98
Returns & Growth
ROE
2.4%
ROA
2.2%
ROIC
0.4%
Rev Growth YoY
+129.1%
EPS Growth YoY
+108.1%
Price Returns
2W
-5.9%
1M
+3.9%
3M
+21.1%
6M
+11.1%
12M
-33.5%
Technicals
52W High
$14.48
52W Low
$8.12
50d MA
$11.01
200d MA
$10.24
RSI (14)
61.00
ATR (14)
$0.58
Beta
0.43
Avg Volume
566K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$23.00
High
$27.00
Low
$19.00
Median
$23.00
Data updated apr 25, 2026 4:49am
· Source: financialmodelingprep.com